NCT07017699View on ClinicalTrials.gov

A Study to Assess Deucravacitinib Safety in Pregnancy

RecruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

February 28, 2029

Conditions
Psoriasis (PsO)
Interventions
DRUG

Deucravacitinib

According to product label

DRUG

Other systemic treatments for PsO

According to product label

Trial Locations (1)

92037

RECRUITING

University of California San Diego, La Jolla

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT07017699 - A Study to Assess Deucravacitinib Safety in Pregnancy | Biotech Hunter | Biotech Hunter